Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
5.24
+0.08 (1.55%)
Dec 20, 2024, 4:00 PM EST - Market closed
Coya Therapeutics Employees
Coya Therapeutics had 8 employees as of December 31, 2023. The number of employees increased by 2 or 33.33% compared to the previous year.
Employees
8
Change (1Y)
2
Growth (1Y)
33.33%
Revenue / Employee
$1,194,289
Profits / Employee
-$1,337,380
Market Cap
87.55M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 8 | 2 | 33.33% |
| Dec 31, 2022 | 6 | 0 | - |
| Dec 31, 2021 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Harvard Bioscience | 416 |
| Veru Inc. | 189 |
| Exagen | 179 |
| Adagene | 174 |
| OptimizeRx | 136 |
| LENSAR | 130 |
| Fractyl Health | 102 |
| HilleVax | 90 |
COYA News
- 3 days ago - Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD) - Business Wire
- 26 days ago - Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference - Business Wire
- 4 weeks ago - Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders - Business Wire
- 6 weeks ago - Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results - Business Wire
- 7 weeks ago - Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer - Business Wire
- 7 weeks ago - Coya Therapeutics: Buying The Dip After Unwarranted Sell-Off - Seeking Alpha
- 7 weeks ago - Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study - Benzinga
- 7 weeks ago - Coya Therapeutics reports positive immune response, safety in mid-stage Alzheimer's drug trial - Reuters